Doğukan Şenberber, M. Yakar, Dilan Delibalta, T. Demir, A. N. Gokmen
{"title":"Successful Treatment of Diabetic Ketoacidosis in a Patient with Insulin Allergy and Coronavirus Disease 2019: A Case Report","authors":"Doğukan Şenberber, M. Yakar, Dilan Delibalta, T. Demir, A. N. Gokmen","doi":"10.5152/tjem.2022.22035","DOIUrl":null,"url":null,"abstract":"Diabetic ketoacidosis is a frequent hyperglycemic emergency. During the coronavirus disease 2019 pandemic, researchers showed a higher prevalence of diabetic ketoacidosis and mortality compared with the preceding years. It is expected that lung involvement in coronavirus disease 2019 decreases compensation capacity for ketoacidosis. Thus, management of the diabetic keto-acidosis is critical in patients with coronavirus disease 2019. Insulin allergy makes the treatment procedure more complicated in these patients. Desensitization procedures or immunomodulatory therapies are not a routine part of treating diabetic ketoacidosis due to the urgency of the disease. Insulin administration to patients with insulin allergy and coronavirus disease 2019 may cause a risk of decreased maintaining oxygenation and compensating for ketoacidosis and endanger airway safety due to possible anaphylaxis. Clinicians should check all preparations for a possible need for anaphylaxis treatment and difficult airway management, including invasive procedures before insulin therapy. Here, we wanted to share a case of successful treatment of diabetic ketoacidosis in a patient with insulin allergy and coronavirus disease 2019. Copyright © Author(s).","PeriodicalId":42868,"journal":{"name":"Turkish Journal of Endocrinology and Metabolism","volume":"4 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Endocrinology and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/tjem.2022.22035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 1
2019年1例胰岛素过敏合并冠状病毒病糖尿病酮症酸中毒的成功治疗
糖尿病酮症酸中毒是一种常见的高血糖急症。在2019年冠状病毒病大流行期间,研究人员发现,与前几年相比,糖尿病酮症酸中毒的患病率和死亡率更高。预计2019冠状病毒病的肺部受累会降低酮症酸中毒的代偿能力。因此,对2019冠状病毒病患者糖尿病酮症酸中毒的管理至关重要。胰岛素过敏使这些患者的治疗过程更加复杂。由于病情的急迫性,脱敏程序或免疫调节疗法不是治疗糖尿病酮症酸中毒的常规部分。对胰岛素过敏和2019冠状病毒病患者进行胰岛素治疗可能会导致维持氧合和补偿酮症酸中毒的风险降低,并因可能的过敏反应而危及气道安全。临床医生应检查所有可能需要过敏反应治疗和困难气道管理的准备工作,包括胰岛素治疗前的侵入性手术。在这里,我们想分享一个成功治疗胰岛素过敏和2019冠状病毒病患者糖尿病酮症酸中毒的案例。版权所有©作者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。